Zhang Yonghong, Yang Zhiya, Gong Jinyan, Shi Dongmei
Shandong University of Traditional Chinese Medicine, Jinan, China.
Laboratory of Medical Mycology, Jining No. 1 People's Hospital, Jining, China.
Front Med (Lausanne). 2024 Mar 6;11:1353893. doi: 10.3389/fmed.2024.1353893. eCollection 2024.
The aims of this study is to analyze the risk of major adverse cardiovascular events (MACEs) in patients with psoriasis treated with secukinumab and ixekizumab.
We systematically identified randomized controlled trials (RCTs) that focused on the treatment of psoriasis with secukinumab and ixekizumab by conducting computerized searches of PubMed, Embase, and the Cochrane Library databases, spanning from their inception to October 31st, 2022. The search terms used included psoriasis, secukinumab, ixekizumab, and randomized controlled trial. Two independent evaluators conducted literature screening, data extraction, and assessed the quality of included studies based on predetermined inclusion and exclusion criteria. The gather data was subjected to meta-analysis using the statistical software RevMan 5.4.
A total of 20 articles, encompassing 23 randomized controlled trials involving 10,746 psoriasis patients were included in the analysis. During the double-blind treatment period, the meta-analysis results indicated the following: There was no significant difference in the incidence of MACEs between the secukinumab and placebo groups [RR = 0.61, 95% CI (0.26, 1.44), = 0.26]. Similarly, there was no significant difference in the incidence of MACEs with ixekizumab compared to the placebo group [RR = 0.47, 95% CI (0.15, 1.47), = 0.20]. Furthermore, no significant difference in the incidence of MACEs was observed between secukinumab 300 mg and secukinumab 150 mg treatment groups [RR = 1.00, 95% CI (0.23, 4.35), = 1.00]. Likewise, there was no significant difference in the incidence of MACEs between the ixekizumab Q4W (every 4 weeks) and ixekizumab Q2W (every 2 weeks) administration groups [RR = 4.01, 95% CI (0.45, 35.89), = 0.21].
The findings of this study suggest that neither secukinumab nor ixekizumab is significantly associated with the risk of MACEs in patients with psoriasis during double-blind treatment.: Unique Identifier: CRD42022373756 https://www.crd.york.ac.uk/.
本研究旨在分析接受司库奇尤单抗和依奇珠单抗治疗的银屑病患者发生主要不良心血管事件（MACE）的风险。
我们通过对PubMed、Embase和Cochrane图书馆数据库进行计算机检索，系统地识别了聚焦于司库奇尤单抗和依奇珠单抗治疗银屑病的随机对照试验（RCT），检索时间跨度从数据库建立至2022年10月31日。使用的检索词包括银屑病、司库奇尤单抗、依奇珠单抗和随机对照试验。两名独立评估者进行文献筛选、数据提取，并根据预定的纳入和排除标准评估纳入研究的质量。收集的数据使用统计软件RevMan 5.4进行荟萃分析。
总共20篇文章被纳入分析，其中包括23项涉及10746例银屑病患者的随机对照试验。在双盲治疗期间，荟萃分析结果表明：司库奇尤单抗组和安慰剂组之间MACE的发生率无显著差异[RR = 0.61，95% CI（0.26，1.44），P = 0.26]。同样，与安慰剂组相比，依奇珠单抗组MACE的发生率也无显著差异[RR = 0.47，95% CI（0.15，1.47），P = 0.20]。此外，司库奇尤单抗300mg治疗组和司库奇尤单抗150mg治疗组之间MACE的发生率无显著差异[RR = 1.00，95% CI（0.23，4.35），P = 1.00]。同样，依奇珠单抗每4周给药组和依奇珠单抗每2周给药组之间MACE的发生率无显著差异[RR = 4.01，95% CI（0.45，35.89），P = 0.21]。
本研究结果表明，在双盲治疗期间，司库奇尤单抗和依奇珠单抗均与银屑病患者发生MACE的风险无显著关联。唯一标识符：CRD42022373756 https://www.crd.york.ac.uk/
